AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9093250 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone
Number of subjects: 80
Study 9093250 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 80
Study 1609761 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (25 mg/d)
Number of subjects: 133
Study 1609761 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (1500 RE/d)
Number of subjects: 133
Study 1609761 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus Vitamin A
Number of subjects: 133
Study 1609761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 3877282 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 73
Study 3877282 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone (2 mg/kg)
Number of subjects: 73
Study 31481323 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for closed ankle fractures with antibiotic prophylaxis
Number of subjects: 998
Study 31481323 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per 10 years)
Number of subjects: 998
Study 31481323 — intervention group
Group type: EXPERIMENTAL
Intervention: Age squared (per 10 years)
Number of subjects: 998
Study 31481323 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (per kg/m2)
Number of subjects: 998
Study 31481323 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index ≥2 vs. 0
Number of subjects: 998
Study 31481323 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index 1 vs. 0
Number of subjects: 998
Study 29174706 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe and non-acute ischemia
Number of subjects: 85
Study 29174706 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-severe and non-acute ischemia
Number of subjects: 85
Study 29174706 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-severe and acute ischemia
Number of subjects: 85
Study 29174706 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe and acute ischemia
Number of subjects: 85
Study 29174706 — intervention group
Group type: COMPARATOR
Intervention: Inferior STEMI
Number of subjects: 85
Study 28840325 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle (SB) technique
Number of subjects: 31
Study 28840325 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) technique
Number of subjects: 31
Study 28840325 — intervention group
Group type: COMPARATOR
Intervention: Preoperative to 6 months postoperative results (both groups)
Number of subjects: 31
Study 28840325 — intervention group
Group type: COMPARATOR
Intervention: IKDC score, Lysholm score, Tegner activity scale, anterior drawer test (both groups)
Number of subjects: 31
Study 23756701 — intervention group
Group type: EXPERIMENTAL
Intervention: High activity neutral protease
Number of subjects: 0
Study 23756701 — intervention group
Group type: COMPARATOR
Intervention: Neutral protease NB GMP grade
Number of subjects: 0
Study 23756701 — intervention group
Group type: COMPARATOR
Intervention: Thermolysin
Number of subjects: 0
Study 21051425 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL PRP (10 times higher platelet concentration than peripheral blood)
Number of subjects: 30
Study 21051425 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 patients, no PRP)
Number of subjects: 30
Study 21051425 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL PRP
Number of subjects: 30
Study 18444145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato products (no soy) for Weeks 0 through 4, targeting a minimum of 25 mg of lycopene/day
Number of subjects: 41
Study 18444145 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy (no tomatoes) for Weeks 0 through 4, providing 40 g of soy protein/day
Number of subjects: 41
Study 18444145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tomato-rich diet and soy supplements for Weeks 4 through 8
Number of subjects: 41
Study 16856945 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives on response rates in a school-based dental study
Number of subjects: 0
Study 16856945 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods for correlated binary data
Number of subjects: 0
Study 12704501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E coated dialyzer (CL‐EE12, Terumo)
Number of subjects: 75
Study 12704501 — intervention group
Group type: COMPARATOR
Intervention: Fresenius 60 (F60) dialyzer
Number of subjects: 75
Study 10561342 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily thoracic irradiation (TDTI)
Number of subjects: 311
Study 10561342 — intervention group
Group type: COMPARATOR
Intervention: Once-daily thoracic irradiation (ODTI)
Number of subjects: 311
Study 9522755 — intervention group
Group type: EXPERIMENTAL
Intervention: Maisto's paste
Number of subjects: 30
Study 9522755 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide-eugenol
Number of subjects: 30
Study 1928770 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia in combination with light general anesthesia (group 2)
Number of subjects: 173
Study 1928770 — intervention group
Group type: COMPARATOR
Intervention: Balanced general anesthesia (group 1)
Number of subjects: 173
Study 6811195 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-releasing IUD
Number of subjects: 110
Study 6811195 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD (30 micrograms/day)
Number of subjects: 110
Study 6811195 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-releasing IUD
Number of subjects: 110
Study 6811195 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD (10 micrograms/day)
Number of subjects: 110
Study 6811195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IUDs
Number of subjects: 110
Study 31972694 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR training
Number of subjects: 19
Study 31972694 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional learning using a technical journal article)
Number of subjects: 19
Study 31254177 — intervention group
Group type: EXPERIMENTAL
Intervention: Related neutral pictures
Number of subjects: 0
Study 31254177 — intervention group
Group type: COMPARATOR
Intervention: Unrelated neutral pictures
Number of subjects: 0
Study 31254177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed condition (distinct processing)
Number of subjects: 0
Study 31254177 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmixed condition (nondistinctive processing)
Number of subjects: 0
Study 29240005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-ring wound protector
Number of subjects: 107
Study 29240005 — intervention group
Group type: COMPARATOR
Intervention: No wound protector (control)
Number of subjects: 107
Study 27152849 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (CBT) guided by a clinician for 8 weeks, comprising 8 modules of written text.
Number of subjects: 56
Study 27152849 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (no intervention).
Number of subjects: 56
Study 24748154 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound-edge protection devices (WEPDs)
Number of subjects: 735
Study 24748154 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 735
Study 22056369 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake nonresectional lung volume reduction surgery
Number of subjects: 63
Study 20705153 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal ring for 3 months
Number of subjects: 71
Study 20705153 — intervention group
Group type: COMPARATOR
Intervention: DMPA alone
Number of subjects: 71
Study 17912164 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 17912164 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 17912164 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 16294814 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropics + intra-aortic balloon pump
Number of subjects: 40
Study 16294814 — intervention group
Group type: COMPARATOR
Intervention: Inotropics
Number of subjects: 40
Study 12045167 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 600 microg/min
Number of subjects: 19
Study 12045167 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/d
Number of subjects: 19
Study 10073079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmann's solution preloading (500 ml)
Number of subjects: 40
Study 10073079 — intervention group
Group type: COMPARATOR
Intervention: No preloading
Number of subjects: 40
Study 7727602 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin 200 IU/kg/day with ferric pyrophosphate 40 mg/day intravenously for 7 days before and 14 days after operation
Number of subjects: 10
Study 7727602 — intervention group
Group type: COMPARATOR
Intervention: Ferric pyrophosphate 40 mg/day alone (control group)
Number of subjects: 10
Study 2024581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-levamisole
Number of subjects: 0
Study 2024581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-leucovorin
Number of subjects: 0
Study 2024581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy and postoperative radiotherapy
Number of subjects: 0
Study 2024581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (alone or combined with leucovorin)
Number of subjects: 0
Study 2024581 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 2024581 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy alone
Number of subjects: 0
Study 7238993 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine Vaginal Cleansing Kit
Number of subjects: 24
Study 7238993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cleansing agent)
Number of subjects: 24
Study 31997087 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 58
Study 31997087 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 58
Study 29529858 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP)
Number of subjects: 362
Study 29529858 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 362
Study 28272230 — intervention group
Group type: EXPERIMENTAL
Intervention: TaperGuard ETT
Number of subjects: 52
Study 28272230 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical ETT
Number of subjects: 52
Study 28272230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 26512604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125%
Number of subjects: 481
Study 26512604 — intervention group
Group type: COMPARATOR
Intervention: Combination of 0.125% ropivacaine + 0.3 μg/mL sufentanil
Number of subjects: 481
Study 26512604 — intervention group
Group type: COMPARATOR
Intervention: Sole local anesthetic group
Number of subjects: 481
Study 24095220 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (C) plus Docetaxel (D)
Number of subjects: 506
Study 24095220 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (D) alone
Number of subjects: 506
Study 22011054 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-based seated dual-task stepping exercise
Number of subjects: 93
Study 22011054 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 93
Study 19656525 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 130
Study 19656525 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 130
Study 17566313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (4 mg)
Number of subjects: 631
Study 17566313 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil-SR (240 mg)
Number of subjects: 631
Study 17566313 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (4 mg) + Verapamil-SR (240 mg) combination
Number of subjects: 631
Study 17566313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study 12911367 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.1 mg.kg‐1
Number of subjects: 400
Study 12911367 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (various doses: 0, 0.025, 0.5, 0.1, 0.175 mg.kg‐1)
Number of subjects: 400
Study 12911367 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.1 mg.kg‐1)
Number of subjects: 400
Study 12911367 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower diazepam doses
Number of subjects: 400
Study 12911367 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher diazepam doses
Number of subjects: 400
Study 11138599 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (Vioxx)
Number of subjects: 0
Study 11138599 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (Celebrex)
Number of subjects: 0
Study 11138599 — intervention group
Group type: COMPARATOR
Intervention: Conventional NSAIDs (diclofenac, ibuprofen, naproxen)
Number of subjects: 0
Study 8815995 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment (A) consisting of postural training, manual technique, and psychological support
Number of subjects: 60
Study 8815995 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (B) using physical agents only (electrical and sonic modalities)
Number of subjects: 60
Study 1357553 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid group (beclomethasone, 800 micrograms daily)
Number of subjects: 274
Study 1357553 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic group (ipratropium bromide, 160 micrograms daily)
Number of subjects: 274
Study 1357553 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 274
Study 4074611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound administration
Number of subjects: 0
Study 4074611 — intervention group
Group type: COMPARATOR
Intervention: Control (no ultrasound)
Number of subjects: 0
Study 2887192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 25 mg day‐1)
Number of subjects: 8
Study 2887192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (PIND, 10 mg day‐1)
Number of subjects: 8
Study 2887192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HCTZ and PIND
Number of subjects: 8
Study 2887192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29906734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully weight-based dosing of chemotherapy (LV5FU2)
Number of subjects: 280
Study 29906734 — intervention group
Group type: COMPARATOR
Intervention: Dose-reduced chemotherapy
Number of subjects: 280
Study 28409365 — intervention group
Group type: EXPERIMENTAL
Intervention: Troubleshooting checklist during second trial
Number of subjects: 20
Study 28409365 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 20
Study 26246032 — intervention group
Group type: EXPERIMENTAL
Intervention: Kenya Cash Transfer for Orphans and Vulnerable Children
Number of subjects: 1549
Study 26246032 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed entry to the program)
Number of subjects: 1549
Study 24138766 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening for tuberculosis (symptom screening, examination, and chest radiography on four occasions over a two-year period)
Number of subjects: 8829
Study 24138766 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening for tuberculosis
Number of subjects: 8829
Study 24138766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active screening)
Number of subjects: 8829
Study 21119149 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular recommendation role (antidepressant for depression, depot for schizophrenia)
Number of subjects: 515
Study 21119149 — intervention group
Group type: EXPERIMENTAL
Intervention: What would you do if you were me, doctor?
Number of subjects: 515
Study 21119149 — intervention group
Group type: EXPERIMENTAL
Intervention: Self role (treatment chosen for themselves)
Number of subjects: 515
Study 18830096 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 400 (90 mL)
Number of subjects: 40
Study 18830096 — intervention group
Group type: COMPARATOR
Intervention: Iomeprol 300 (120 mL)
Number of subjects: 40
Study 18830096 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 400
Number of subjects: 40
Study 18830096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 40
Study 17015530 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation plus pressure support
Number of subjects: 107
Study 17015530 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation
Number of subjects: 107
Study 17015530 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation plus pressure support (700-1000 g birth weight strata)
Number of subjects: 107
Study 12686409 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with RR-MS
Number of subjects: 47
Study 12686409 — intervention group
Group type: COMPARATOR
Intervention: Women with RR-MS
Number of subjects: 47
Study 12686409 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with RR-MS
Number of subjects: 47
Study 12686409 — intervention group
Group type: COMPARATOR
Intervention: Males with RR-MS
Number of subjects: 47
Study 11078264 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 130
Study 8836781 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 65
Study 8836781 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia with sedation analgesia
Number of subjects: 65
Study 1605596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg
Number of subjects: 48
Study 1605596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg
Number of subjects: 48
Study 1605596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6383998 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous administration of vasopressin
Number of subjects: 37
Study 6383998 — intervention group
Group type: COMPARATOR
Intervention: Sengstaken‐Blakemore balloon tamponade
Number of subjects: 37
Study 6383998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality in vasopressin group
Number of subjects: 37
Study 6383998 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality in tamponade group
Number of subjects: 37
Study 6383998 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled bleeding mortality
Number of subjects: 37
Study 6383998 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications of treatment mortality
Number of subjects: 37
Study 30895583 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic pancreatic duct stenting (PPDS)
Number of subjects: 24
Study 30895583 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 24
Study 29181814 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training after memory retrieval
Number of subjects: 0
Study 29181814 — intervention group
Group type: COMPARATOR
Intervention: Working memory training prior to memory retrieval (Control)
Number of subjects: 0
Study 27823685 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic endovascular aortic repair (TEVAR)
Number of subjects: 114
Study 27823685 — intervention group
Group type: COMPARATOR
Intervention: Conservative (medical) management
Number of subjects: 114
Study 25091714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000-U bolus intramuscularly plus 50,000 U orally weekly)
Number of subjects: 130
Study 25091714 — intervention group
Group type: COMPARATOR
Intervention: Asthma controllers (budesonide or budesonide plus formoterol)
Number of subjects: 130
Study 22762173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Sulphate (FS)
Number of subjects: 93
Study 22762173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 93
Study 20522283 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar-dorsal splinting (VDS)
Number of subjects: 101
Study 20522283 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential casting (CC)
Number of subjects: 101
Study 20522283 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sugar-tong splinting (MST)
Number of subjects: 101
Study 20522283 — intervention group
Group type: COMPARATOR
Intervention: All groups (CC, VDS, MST)
Number of subjects: 101
Study 17984125 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria-specific T-cell responses
Number of subjects: 117
Study 17984125 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of T cells
Number of subjects: 117
Study 16485863 — intervention group
Group type: EXPERIMENTAL
Intervention: Traveling Salesman Problem (TSP)
Number of subjects: 45
Study 16485863 — intervention group
Group type: COMPARATOR
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 45
Study 11876600 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with pullulan‐conjugated antigen (CS‐560)
Number of subjects: 23
Study 11876600 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-IT)
Number of subjects: 23
Study 10992846 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep topical fornix nerve block anaesthesia (DTFNBA)
Number of subjects: 120
Study 10992846 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar nerve block
Number of subjects: 120
Study 9001651 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (ACV) 5‐80 mg/kg daily in four divided doses
Number of subjects: 65
Study 9001651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACV)
Number of subjects: 65
Study 1483856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (2 g/day)
Number of subjects: 101
Study 1483856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 1483856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (dose titration up to 4 g/day)
Number of subjects: 101
Study 4006263 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenylpropanolamine (PPA) 25 mg/ml
Number of subjects: 10